Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24717621 | 1.00 | HTR6 (0.36) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24718725 | 0.92 | HTR6 (0.40) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL21816767 | 0.86 | HPGD (0.38) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24718111 | 0.81 | DRD2 (0.38) | HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24718729 | 0.81 | KHK (0.32) | HTR6 | |
| SCHEMBL24995530 | 0.79 | HRH3 (0.37) | HTR6 | |
| SCHEMBL24996299 | 0.79 | HRH3 (0.34) | — | |
| SCHEMBL24718323 | 0.79 | HRH3 (0.37) | HTR6 | |
| SCHEMBL23267620 | 0.77 | HRH3 (0.40) | HTR6 | |
| SCHEMBL23267623 | 0.77 | HRH3 (0.40) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | HTR6 2074/4885HPGD 4244/4885KMT2A 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.